微血管阻塞与STEMI直接PCI后不良事件的关系:七项随机试验的个体患者数据汇总分析
该研究汇总七项随机直接PCI试验的1688例STEMI患者个体数据,用心脏磁共振在再灌注后7天内评估微血管阻塞(MVO)。MVO存在者占56.9%,MVO范围每增加1.0%与全因死亡和心衰住院风险独立相关,但与再发心梗无显著关联。
要点
- 直接PCI后CMR评估的MVO存在及范围与1年内全因死亡和心衰住院独立相关。
- MVO范围每增加1.0%,全因死亡风险调整后HR为1.14,心衰住院HR为1.08。
- MVO与再发心梗无显著关联(P=0.29)。
核心结论
- STEMI直接PCI后CMR评估的MVO存在及范围与1年内全因死亡和心衰住院强烈相关,与再发心梗无显著关联。
研究设计与样本
- 汇总七项随机直接PCI试验的个体患者数据,共1688例STEMI患者,CMR在再灌注后7天内完成。
- CMR评估采用晚期钆增强成像,临床随访至少6个月。
- CMR中位时间为STEMI后3天(IQR 2-4),临床随访中位时间365天(IQR 188-374)。
主要发现
- 960例(56.9%)患者存在MVO,MVO中位范围(占左心室心肌质量百分比)为0.47%(IQR 0.00-2.54)。
- MVO范围每绝对增加1.0%,全因死亡调整后HR 1.14(95%CI 1.09-1.19,P<0.0001),心衰住院调整后HR 1.08(95%CI 1.05-1.12,P<0.0001)。
- 进一步调整梗死面积后,MVO仍与全因死亡显著相关(调整后HR 1.09,95%CI 1.01-1.17,P=0.03)。
- MVO与后续再发心梗无显著关联(P=0.29)。
临床怎么用
- 对STEMI直接PCI后患者,可考虑用CMR评估MVO以辅助风险分层,识别死亡和心衰住院高危者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Microvascular obstruction (MVO) is the underlying cause for the no-reflow phenomenon in ST-segment elevation myocardial infarction (STEMI). The association between MVO assessed by cardiac magnetic resonance imaging (CMR) and prognosis has not been convincingly demonstrated. We sought to determine the relationship between MVO assessed early after primary percutaneous coronary intervention (PCI) in STEMI and all-cause mortality, hospitalization for heart failure (HF), and reinfarction. METHODS AND RESULTS: We performed a pooled analysis using individual patient data from seven randomized primary PCI trials in which MVO was assessed within 7 days after reperfusion by CMR using late gadolinium enhancement imaging (n = 1688). Clinical follow-up was performed for at least 6 months after the index event. Median time to CMR after STEMI was 3 days [interquartile range (IQR) 2-4], and median duration of clinical follow-up was 365 days (IQR 188-374). Microvascular obstruction was present in 960 (56.9%) of patients, and median MVO (percent left ventricular myocardial mass) was 0.47% (IQR 0.00-2.54). A graded response was present between the extent of MVO (per 1.0% absolute increase) and subsequent mortality [Cox adjusted hazard ratio (HR) 1.14, 95% confidence interval (CI) 1.09-1.19, P < 0.0001] and hospitalization for HF (Cox adjusted HR 1.08, 95% CI 1.05-1.12, P < 0.0001). Microvascular obstruction remained significantly associated with all-cause mortality even after further adjustment for infarct size (Cox adjusted HR 1.09, 95% CI 1.01-1.17, P = 0.03). MVO was not significantly related to subsequent reinfarction (P = 0.29). CONCLUSIONS: The presence and extent of MVO measured by CMR after primary PCI in STEMI are strongly associated with mortality and hospitalization for HF within 1 year.
引用
- de Waha S, Patel MR, Granger CB, et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. Eur Heart J. 2017. PMID: 29020248. doi:10.1093/eurheartj/ehx414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。